435 Pill: brown, capsule/oblong, 19mm
The pill with imprint 435 (Brown, Capsule/Oblong, 19mm) has been identified as Mesalamine Delayed-Release 800 mg and is used for Ulcerative Colitis, Maintenance, Ulcerative Colitis, Active, Crohn's Disease, Maintenance, Inflammatory Bowel Disease, and Ulcerative Proctitis. It belongs to the drug class 5-aminosalicylates and is not a controlled substance.
Images for 435
Mesalamine Delayed-Release
- Imprint
- 435
- Strength
- 800 mg
- Color
- Brown
- Size
- 19.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- 5-aminosalicylates
- Pregnancy Category
- B - No proven risk in humans - excluding Asacol and Asacol HD, C - Risk cannot be ruled out - Asacol and Asacol HD
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Zydus Pharmaceuticals (USA) Inc.
- Manufacturer
- Cadila Healthcare Limited
- National Drug Code (NDC)
- 70771-1110
- Inactive Ingredients
-
acetyltributyl citrate,
silicon dioxide,
ferric oxide red,
magnesium stearate,
methacrylic acid,
microcrystalline cellulose,
povidone,
sodium starch glycolate type A potato,
magnesium silicate,
titanium dioxide,
ferrosoferric oxide,
isopropyl alcohol,
butyl alcohol,
propylene glycol,
ammonia,
shellac
Note: Inactive ingredients may vary.
Related images for "435"
More about mesalamine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (426)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: 5-aminosalicylates
- Breastfeeding
Patient resources
- Mesalamine drug information
- Mesalamine rectal
- Mesalamine (Oral) (Advanced Reading)
- Mesalamine (Rectal) (Advanced Reading)
Other brands
Lialda, Apriso, Pentasa, Delzicol, ... +4 more
Professional resources
- Mesalamine monograph
- Mesalamine (FDA)
- Mesalamine Capsules (FDA)
- Mesalamine Controlled-Release Capsules (FDA)
- Mesalamine Delayed Release Tablets (FDA)
Other brands
Lialda, Apriso, Pentasa, Asacol, ... +5 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.